

**P11-16. Transfer of HIV-1 from Langerhans and interstitial dendritic cells to T lymphocytes: protection mediated by antibodies?**

Maryse Peressin, Vincent Holl, Sylvie Schmidt, Thomas Decoville, J Penichon, Christiane Moog

► **To cite this version:**

Maryse Peressin, Vincent Holl, Sylvie Schmidt, Thomas Decoville, J Penichon, et al.. P11-16. Transfer of HIV-1 from Langerhans and interstitial dendritic cells to T lymphocytes: protection mediated by antibodies?. Anna Laura Ross. AIDS Vaccine 2009, Oct 2009, Paris, France. BioMed Central, 6 (Suppl 3), pp.P161, 2009, Retrovirology. <10.1186/1742-4690-6-S3-P161>. <inserm-00663924>

**HAL Id: inserm-00663924**

**<http://www.hal.inserm.fr/inserm-00663924>**

Submitted on 27 Jan 2012

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Poster presentation

## **PII-16. Transfer of HIV-1 from Langerhans and interstitial dendritic cells to T lymphocytes: protection mediated by antibodies?**

M Peressin, V Holl, S Schmidt, T Decoville, J Penichon and C Moog\*

Address: UMR INSERM/UDS, Strasbourg, France

\* Corresponding author

from AIDS Vaccine 2009  
Paris, France. 19–22 October 2009

Published: 22 October 2009

*Retrovirology* 2009, **6**(Suppl 3):P161 doi:10.1186/1742-4690-6-S3-P161

This abstract is available from: <http://www.retrovirology.com/content/6/S3/P161>

© 2009 Peressin et al; licensee BioMed Central Ltd.

### **Background**

Langerhans (LC) and interstitial dendritic cells (IDC) present in mucosal tissues are among the first HIV-1 target cells. Infected DC have been shown to transfer the virus to nearby CD4 T lymphocytes. We have demonstrated that neutralizing antibodies (NAb) were able to inhibit the transfer of HIV-1 from monocyte-derived DC to CD4-T lymphocytes. In the context of HIV-1 transmission at mucosal site, we analysed the transfer of HIV-1 from LC and IDC to CD4-T lymphocytes, and determined the capacity of NAb to inhibit this transfer.

### **Methods**

LC and IDC were obtained by differentiation of CD34+ cord blood cells. Immature LC/IDC were infected during 2 hours with HIV-1 and extensively washed prior to the coculture with primary lymphocytes or CD4-T cell lines, in presence or absence of NAb. HIV-1 infection was determined by the detection of infected cells by intracellular p24-staining and flow cytometry analysis, or by the quantification of HIV-1 released in the supernatant by p24-ELISA dosage.

### **Results**

We demonstrated that LC and IDC transfer HIV-1 to T lymphocytes. Moreover, neutralizing antibodies efficiently inhibit HIV-1 replication CD4-T lymphocytes when cocultured with infected LC/IDC. These results show that HIV-1 transfer to CD4-T cells is not resistant to neutralization. Surprisingly, when primary CD4-T or non-

permissive B lymphocytes were cocultured with HIV-1 exposed DC, a strong stimulation of HIV-1 production was detected in LC and IDC. This augmentation was not observed in the coculture of LC/IDC with CD4-T cell lines.

### **Conclusion**

Altogether, these data demonstrate that, in the mucosal context where DC and T or B lymphocytes are in close contact, infected DC may become highly HIV replicating cells. As Ab were able to efficiently inhibit HIV-1 transfer from LC/IDC to T lymphocytes, they should be locally induced at the mucosal site by vaccination to prevent HIV-1 dissemination.